Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

491.64 +5.68 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2 3 4 5 6 7 Next >
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
The Latest Analyst Ratings for argenx
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
What 20 Analyst Ratings Have To Say About argenx
Via Benzinga
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
Via Investor's Business Daily
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
These stocks could lead if the market rallies. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Is Argenx Stock a Buy Now?
Good news keeps rolling in for the biotech. 
Via The Motley Fool
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market
Arista Networks and Dutch biotech Argenx lead this weekend's watch list. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
Earnings Outlook For argenx
Via Benzinga
argenx Unusual Options Activity
Via Benzinga
Why Shares of Argenx Jumped This Week
The company's lead therapy showed progress in treating an autoimmune disorder. 
Via The Motley Fool
The Latest Analyst Ratings for argenx
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week. 
Via Investor's Business Daily
argenx announces closing of global offering
From argenx SE
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.